Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
我武生物
300357
Shenzhen Stock Exchange
Company Profile
The pharmaceutical manufacturing industry is highly innovative, while technological innovation and upgrading of medical products may bring revolutionary changes to the entire industry. Therefore, the decisive factors to occupy a leading position in the industry are independent research and development capabilities and technological innovation capabilities. The company owns a highly competitive R&D team with a reasonable age structure and relatively good stability that is able to grasp important development opportunities of technology update and product replacement. This assures continuity and foresight for Wolwo’s R&D. Until today, there are only 3 dust mite desensitization drugs approved by the Chinese National Medical Products Administration: Dermatophagoides Farinae Drops, Mites allergens ALK (503) D.p, and Novo-Helisen-Depot, most of which are injected subcutaneously, with the exception of Wolwo’s Dermatophagoides Farinae Drops，which is taken sublingually. This product is safe, easy to use, and high portable. Wolwo's product Artemisia Annua Allergens Sublingual Immunotherapy Drops was approved and issued by the Chinese National Medical Products Administration on 30 January 2021. According to the Chinese National Medical Products Administration's official website, there are by far no products of the same variety. Wolwo's competitiveness continue to lead the field.
Full description
Wolwo Pharma is a high-tech biopharmaceutical company specializing in the research and development, production as well as sales of allergic disease diagnosis and treatment products. As leader in the allergenic immunotherapy market in China, Wolwo is also actively promoting research and development in other fields including stem cells, natural medicines (antibiotics for drug-resistant bacterial strains) etc. Dermatophagoides Farinae Drops, Artemisia Annua Allergens Sublingual Immunotherapy Drops and skin prick solution are its current main products. The company's leading product Dermatophagoides Farinae Drops is used for allergic rhinitis and allergic asthma due to Dermatophagoides farinae. As the optimal living condition for a dust mite is 20℃-30℃ in temperature with a relative humidity of 70%-80%, summer and autumn are most suitable for their reproduction. Consequently, allergic diseases due to dust mites occur frequently during these seasons. Meanwhile, allergic diseases are more common in highly industrialized areas. Regional distribution of allergens result in allergies. For example, patients in southern regions are more likely to be allergic to Dermatophagoides farinae, while patients in northern region are more likely to be allergic to Artemisia annua/Artemisia vulgaris pollen. The company’s product Artemisia Annua Allergens Sublingual Immunotherapy Drops and the company's leading product Dermatophagoides Farinae Drops complement to provide desensitization immunotherapy for a wider spectrum of allergens and benefit more patients.